Spero Therapeutics, Inc. (SPRO)
After hours:
| Previous close | 1.6900 |
| Open | 1.7200 |
| Bid | 1.5900 x 300 |
| Ask | 1.6800 x 100 |
| Day's range | 1.6100 - 1.7200 |
| 52-week range | 0.9900 - 1.9400 |
| Volume | |
| Avg. volume | 317,446 |
| Market cap | 91.079M |
| Beta (5Y monthly) | 0.62 |
| PE ratio (TTM) | 3.81 |
| EPS (TTM) | 0.4300 |
| Earnings date | 15 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.50 |
Simply Wall St.Shareholders in Spero Therapeutics (NASDAQ:SPRO) are in the red if they invested three years ago
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders should be happy to see the share price up 23% in the last...
GlobeNewswireSpero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close. The Company does not intend to host a conference cal
- GlobeNewswire
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on April 29, 2024, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 10,833 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics,
